Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa

Sidra Hassan, Mani D. Kahn, Nidhi Saraiya, Priya Nori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.

Original languageEnglish (US)
JournalBMJ Case Reports
Volume2018
DOIs
StatePublished - Jan 5 2018

Fingerprint

Pseudomonas aeruginosa
Orthopedics
United States Food and Drug Administration
Infection
Pharmaceutical Preparations
Osteomyelitis
Centers for Disease Control and Prevention (U.S.)
Cross Infection
Urinary Tract Infections
Upper Extremity
Joints
Anti-Bacterial Agents
Bone and Bones
tazobactam drug combination ceftolozane

Keywords

  • drugs: infectious diseases
  • infections
  • musculoskeletal and joint disorders
  • skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa. / Hassan, Sidra; Kahn, Mani D.; Saraiya, Nidhi; Nori, Priya.

In: BMJ Case Reports, Vol. 2018, 05.01.2018.

Research output: Contribution to journalArticle

@article{2b0463661a4641e29c06de7a97ceed50,
title = "Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa",
abstract = "According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13{\%}) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.",
keywords = "drugs: infectious diseases, infections, musculoskeletal and joint disorders, skin",
author = "Sidra Hassan and Kahn, {Mani D.} and Nidhi Saraiya and Priya Nori",
year = "2018",
month = "1",
day = "5",
doi = "10.1136/bcr-2017-223202",
language = "English (US)",
volume = "2018",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa

AU - Hassan, Sidra

AU - Kahn, Mani D.

AU - Saraiya, Nidhi

AU - Nori, Priya

PY - 2018/1/5

Y1 - 2018/1/5

N2 - According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.

AB - According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.

KW - drugs: infectious diseases

KW - infections

KW - musculoskeletal and joint disorders

KW - skin

UR - http://www.scopus.com/inward/record.url?scp=85051196339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051196339&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-223202

DO - 10.1136/bcr-2017-223202

M3 - Article

VL - 2018

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -